Novartis, the Swiss pharmaceutical company, has halted its phase 3 study of the biologic drug ligelizumab for peanut allergy this January, but plans to launch a new study at a different dose. If approved, the study will begin in Autumn 2024.
The 52-week terminated study aimed to test the safety and efficacy of two doses ligelizumab in patients with confirmed peanut allergy. The drug was intended to increase tolerance of peanuts to prevent allergic reactions.
The news comes soon after the Food and Drug Administration (FDA) announced it is giving priority review to another drug called omalizumab (Xolair) as a food allergy treatment. Xolair is another injectable drug which Novartis is co-developing with Genentech. If the FDA approves its use in food allergy, Xolair will become the first anti-IgE drug for reducing reactions to multiple food allergens.
Read more about the study on ClinicalTrials.gov
Provide your email address to receive our printable guide outlining emergency symptoms and actions.
Additionally, enjoy our monthly Allergy Outlook email, delivering the latest news, updates, and resources directly to your inbox.